Buscar
Schrodinger Inc
SDGRAñadir a la lista de seguimiento
16.880USD
+0.490+2.99%
Cierre 07/02, 13:00（ET）Cotizaciones retrasadas 15 min
1.26BCap. mercado
PérdidaP/E TTM
Más Datos de Schrodinger Inc Compañía
Schrodinger, Inc. operates a physics-based computational platform that enables the discovery of molecules for drug development and materials applications. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Its segments include Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in the material science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The Company's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor), and others. Its software has been used by researchers around the world at more than 1,818 academic institutions.
Información de Schrodinger Inc
Símbolo de cotizaciónSDGR
Nombre de la empresaSchrodinger Inc
Fecha de salida a bolsaFeb 06, 2020
Director ejecutivoFarid (Ramy Farid)
Número de empleados891
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 06
Dirección1540 Broadway
CiudadNEW YORK
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal10036
Teléfono15032991150
Sitio Webhttps://www.schrodinger.com
Símbolo de cotizaciónSDGR
Fecha de salida a bolsaFeb 06, 2020
Director ejecutivoFarid (Ramy Farid)
Ejecutivos de Schrodinger Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Richard A. Friesner, Ph.D.
Dr. Richard A. Friesner, Ph.D.
Director
Director
1.41M
+0.58%
Mr. Kenneth Patrick (Patrick) Lorton
Mr. Kenneth Patrick (Patrick) Lorton
Executive Vice President, Chief Operating Officer - Software
Executive Vice President, Chief Operating Officer - Software
72.66K
+50.36%
Ms. Margaret Dugan, M.D.
Ms. Margaret Dugan, M.D.
Chief Medical Officer
Chief Medical Officer
24.57K
-5.68%
Dr. Rosana Kapeller-Libermann, M.D., Ph.D.
Dr. Rosana Kapeller-Libermann, M.D., Ph.D.
Independent Director
Independent Director
19.39K
+41.98%
Mr. Arun Oberoi
Mr. Arun Oberoi
Independent Director
Independent Director
19.39K
+41.98%
Ms. Bridget Anne Van Kralingen
Ms. Bridget Anne Van Kralingen
Independent Director
Independent Director
11.47K
+70.95%
Ms. Yvonne Tran, J.D.
Ms. Yvonne Tran, J.D.
Chief People Officer, Executive Vice President, Chief Legal Officer
Chief People Officer, Executive Vice President, Chief Legal Officer
10.49K
-402.13%
Dr. Ramy Farid, Ph.D.
Dr. Ramy Farid, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Robert Abel, Ph.D.
Dr. Robert Abel, Ph.D.
Executive Vice President, Chief Scientific Officer, Platform
Executive Vice President, Chief Scientific Officer, Platform
--
--
Dr. Karen Akinsanya, Ph.D.
Dr. Karen Akinsanya, Ph.D.
President - R&D Therapeutics
President - R&D Therapeutics
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Richard A. Friesner, Ph.D.
Dr. Richard A. Friesner, Ph.D.
Director
Director
1.41M
+0.58%
Mr. Kenneth Patrick (Patrick) Lorton
Mr. Kenneth Patrick (Patrick) Lorton
Executive Vice President, Chief Operating Officer - Software
Executive Vice President, Chief Operating Officer - Software
72.66K
+50.36%
Ms. Margaret Dugan, M.D.
Ms. Margaret Dugan, M.D.
Chief Medical Officer
Chief Medical Officer
24.57K
-5.68%
Dr. Rosana Kapeller-Libermann, M.D., Ph.D.
Dr. Rosana Kapeller-Libermann, M.D., Ph.D.
Independent Director
Independent Director
19.39K
+41.98%
Mr. Arun Oberoi
Mr. Arun Oberoi
Independent Director
Independent Director
19.39K
+41.98%
Ms. Bridget Anne Van Kralingen
Ms. Bridget Anne Van Kralingen
Independent Director
Independent Director
11.47K
+70.95%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Schrodinger Inc?
Los cinco principales accionistas de Schrodinger Inc son: Dr. Richard A. Friesner, Ph.D.
¿Cuántas instituciones poseen acciones de Schrodinger Inc (SDGR)?
A fecha de 2026Q1, 525 instituciones poseen acciones de Schrodinger Inc, con un valor de mercado combinado de aproximadamente 71.93M, lo que representa el 109.89% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -7222611.00.
¿Cuál es la mayor fuente de ganancias de Schrodinger Inc?
El 2026Q1, el segmento empresarial On-premise software generó la ganancia más alta para Schrodinger Inc, ascendiendo a 101.45M y representando el 39.65% de la ganancia total.